Oxidative stress, neurodegeneration, and the balance of protein degradation and protein synthesis

Free Radical Biology and Medicine

Volumn 62, Issue , 2013, Pages 170-185

  Dasuri, Kalavathi ^a   Zhang, Le ^a   Keller, Jeffrey N ^a  

^a PENNINGTON BIOMEDICAL RESEARCH CENTER   (United States)

Author keywords

Antioxidant; Autophagy; Free radical; Lysosome; Proteasome; Protein synthesis; Proteolysis; Reactive oxygen species

Indexed keywords

4 HYDROXYNONENAL; ALPHA TOCOPHEROL; ASCORBIC ACID; BETA CAROTENE; CALPAIN; CATALASE; CYSTINE; FLAVONOID; GLUTATHIONE; GLUTATHIONE PEROXIDASE; HUNTINGTIN; MALONALDEHYDE; MATRIX METALLOPROTEINASE; OMEGA 3 FATTY ACID; PARKIN; PEROXIREDOXIN; PHENOL DERIVATIVE; PROTEASOME; PROTEIN; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; SUPEROXIDE DISMUTASE; SYNUCLEIN; THIOREDOXIN; UBIQUINONE; UBIQUITIN; XANTHINE OXIDASE;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; AUTOPHAGY; CEREBROVASCULAR ACCIDENT; DEGENERATIVE DISEASE; DIET SUPPLEMENTATION; GENE MUTATION; HUMAN; HUNTINGTON CHOREA; HYDROPHOBICITY; LIPID PEROXIDATION; NERVE DEGENERATION; NITROSYLATION; NONHUMAN; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PARKINSON DISEASE; PEROXISOME; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN SYNTHESIS; PROTEIN UNFOLDING; REVIEW;

EID: 84884863139     PISSN: 08915849     EISSN: 18734596     Source Type: Journal    
DOI: 10.1016/j.freeradbiomed.2012.09.016     Document Type: Review

References (272)

1. Sies, H. Oxidative stress: oxidants and antioxidants. Exp. Physiol. 82: 291-295; 1997. (Pubitemid 27182306)
2. Bienert, G. P.; Schjoerring, J. K.; Jahn, T. P. Membrane transport of hydrogen peroxide. Biochim. Biophys. Acta 1758: 994-1003; 2006. (Pubitemid 44373854)
3. Finkel, T. Oxidant signals and oxidative stress. Curr. Opin. Cell Biol. 15: 247-254; 2003. (Pubitemid 36332201)
4. Smythies, J. The neurotoxicity of glutamate, dopamine, iron and reactive oxygen species: functional interrelationships in health and disease: a review-discussion. Neurotox. Res 1: 27-39; 1999.
5. Stone, J. R.; Yang, S. Hydrogen peroxide: a signaling messenger. Antioxid. Redox Signaling 8: 243-270; 2006. (Pubitemid 43741296)
6. Halliwell, B.; Whiteman, M. Measuring reactive species and oxidative damage in vivo and in cell culture: how should you do it and what do the results mean? Br J. Pharmacol. 142: 231-255; 2004. (Pubitemid 38746160)
7. Halliwell, B. Oxidative stress and neurodegeneration: where are we now? J. Neurochem. 97: 1634-1658; 2006. (Pubitemid 43873658)
8. Andersen, J. K. Oxidative stress in neurodegeneration: cause or consequence? Nat. Med. 10(Suppl):S18-S25; 2004. (Pubitemid 38901863)
9. Rivas-Arancibia, S., et al. Oxidative stress and neurodegenerative disease. In: Chang, R. Chuen-Chung, editor. Neurodegenerative Diseases - Processes, Prevention, Protection and Monitoring. New York: InTech; 2011.
10. Beal, M. F. Mitochondria take center stage in aging and neurodegeneration. Ann. Neurol. 58: 495-505; 2005. (Pubitemid 41377212)
11. Droge, W. Free radicals in the physiological control of cell function. Physiol. Rev. 82: 47-95; 2002. (Pubitemid 34654215)
12. Turrens, J. F. Mitochondrial formation of reactive oxygen species. J. Physiol. 552: 335-344; 2003. (Pubitemid 37321833)
13. Valko, M.; Leibfritz, D.; Moncol, J.; Cronin, M. T.; Mazur, M.; Telser, J. Free radicals and antioxidants in normal physiological functions and human disease. Int. J. Biochem. Cell Biol. 39: 44-84; 2007. (Pubitemid 44566469)
14. Valko, M.; Morris, H.; Metals, Cronin M. T. toxicity and oxidative stress. Curr. Med. Chem. 12: 1161-1208; 2005.
15. Kang, J.; Pervaiz, S. Mitochondria: redox metabolism and dysfunction. Biochem. Res. Int. 2012: 896751; 2012.
16. Bruce-Keller, A. J.; Gupta, S.; Knight, A. G.; Beckett, T. L.; McMullen, J. M.; Davis, P. R., et al. Cognitive impairment in humanized APPxPS1 mice is linked to Abeta(1-42) and NOX activation. Neurobiol. Dis. 44: 317-326; 2011.
17. Shimohama, S.; Tanino, H.; Kawakami, N.; Okamura, N.; Kodama, H.; Yamaguchi, T., et al. Activation of NADPH oxidase in Alzheimer's disease brains. Biochem. Biophys. Res. Commun. 273: 5-9; 2000. (Pubitemid 30426853)
18. Block, M. L. N. A. D. P. H. oxidase as a therapeutic target in Alzheimer's disease. BMC Neurosci 9(Suppl. 2):S8; 2008.
19. Lambeth, J. D. Nox enzymes, ROS, and chronic disease: an example of antagonistic pleiotropy. Free Radic. Biol. Med. 43: 332-347; 2007. (Pubitemid 46992767)
20. Hyun, D. H.; Emerson, S. S.; Jo, D. G.; Mattson, M. P.; de, C. R. Calorie restriction up-regulates the plasma membrane redox system in brain cells and suppresses oxidative stress during aging. Proc. Natl. Acad. Sci. USA 103: 19908-19912; 2006. (Pubitemid 46037529)
21. Hyun, D. H.; Mughal, M. R.; Yang, H.; Lee, J. H.; Ko, E. J.; Hunt, N. D., et al. The plasma membrane redox system is impaired by amyloid b-peptide and in the hippocampus and cerebral cortex of 3xTgAD mice. Exp. Neurol. 225: 423-429; 2010.
22. Abe, Y.; Hashimoto, Y.; Tomita, Y.; Terashita, K.; Aiso, S.; Tajima, H., et al. Cytotoxic mechanisms by M239V presenilin 2, a little-analyzed Alzheimer's disease-causative mutant. J. Neurosci. Res. 77: 583-595; 2004. (Pubitemid 39007010)
23. Muir, S. W. Harrow C., Dawson J., Lees K.R., Weir C.J., Sattar N., et al. Allopurinol use yields potentially beneficial effects on inflammatory indices in those with recent ischemic stroke: a randomized, double-blind, placebo-controlled trial. Stroke 39: 3303-3307; 2008.
24. Bredt, D. S. Endogenous nitric oxide synthesis: biological functions and pathophysiology. Free Radic. Res. 31: 577-596; 1999.
25. Tweedie, D.; Frankola, K. A.; Luo, W.; Li, Y.; Greig, N. H. Thalidomide analogues suppress lipopolysaccharide-induced synthesis of TNF-alpha and nitrite, an intermediate of nitric oxide, in a cellular model of inflammation. Open Biochem. J. 5: 37-44; 2011.
26. Hawkins, C. L.; Morgan, P. E.; Davies, M. J. Quantification of protein modification by oxidants. Free Radic. Biol. Med. 46: 965-988; 2009.
27. Dasuri, K.; Ebenezer, P.; Zhang, L.; Fernandez-Kim, S. O.; Bruce-Keller, A. J.; Markesbery, W. R., et al. Increased protein hydrophobicity in response to aging and Alzheimer disease. Free Radic. Biol. Med. 48: 1330-1337; 2010.
28. Hartley, D. P.; Kolaja, K. L.; Reichard, J.; Petersen, D. R. 4-Hydroxynonenal and malondialdehyde hepatic protein adducts in rats treated with carbon tetrachloride: immunochemical detection and lobular localization. Toxicol. Appl. Pharmacol. 161: 23-33; 1999.
29. Shacter, E. Quantification and significance of protein oxidation in biological samples. Drug Metab. Rev. 32: 307-326; 2000. (Pubitemid 32001909)
30. Shulaev, V.; Oliver, D. J. Metabolic and proteomic markers for oxidative stress: new tools for reactive oxygen species research. Plant Physiol. 141: 367-372; 2006. (Pubitemid 43974529)
31. Tarpey, M. M.; Wink, D. A.; Grisham, M. B. Methods for detection of reactive metabolites of oxygen and nitrogen: in vitro and in vivo considerations. Am. J. Physiol. Regul. Integr. Comp. Physiol. 286:R431-R444; 2004. (Pubitemid 38252605)
32. Kalyanaraman, B.; Darley-Usmar, V.; Davies, K. J.; Dennery, P. A.; Forman, H. J.; Grisham, M. B., et al. Measuring reactive oxygen and nitrogen species with fluorescent probes: challenges and limitations. Free Radic. Biol. Med. 52: 1-6; 2012.
33. Celsi, F.; Ferri, A.; Casciati, A.; D'Ambrosi, N.; Rotilio, G.; Costa, A., et al. Overexpression of superoxide dismutase 1 protects against beta-amyloid peptide toxicity: effect of estrogen and copper chelators. Neurochem. Int. 44: 25-33; 2004. (Pubitemid 37101140)
34. Li, F.; Calingasan, N. Y.; Yu, F.; Mauck, W. M.; Toidze, M.; Almeida, C. G., et al. Increased plaque burden in brains of APP mutant MnSOD heterozygous knockout mice. J. Neurochem. 89: 1308-1312; 2004. (Pubitemid 38715849)
35. Murakami, K.; Murata, N.; Noda, Y.; Tahara, S.; Kaneko, T.; Kinoshita, N., et al. SOD1 (copper/zinc superoxide dismutase) deficiency drives amyloid beta protein oligomerization and memory loss in mouse model of Alzheimer disease. J. Biol. Chem. 286: 44557-44568; 2011.
36. Rosen, D. R.; Siddique, T.; Patterson, D.; Figlewicz, D. A.; Sapp, P.; Hentati, A., et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 362: 59-62; 1993. (Pubitemid 23087289)
37. Jung, J. E.; Kim, G. S.; Narasimhan, P.; Song, Y. S.; Chan, P. H. Regulation of Mn-superoxide dismutase activity and neuroprotection by STAT3 in mice after cerebral ischemia. J. Neurosci. 29: 7003-7014; 2009.
38. Ho, Y. S.; Xiong, Y.; Ma, W.; Spector, A.; Ho, D. S. Mice lacking catalase develop normally but show differential sensitivity to oxidant tissue injury. J. Biol. Chem. 279: 32804-32812; 2004. (Pubitemid 39014740)
39. Baker, K.; Marcus, C. B.; Huffman, K.; Kruk, H.; Malfroy, B.; Doctrow, S. R. Synthetic combined superoxide dismutase/catalase mimetics are protective as a delayed treatment in a rat stroke model: a key role for reactive oxygen species in ischemic brain injury. J. Pharmacol. Exp. Ther. 284: 215-221; 1998. (Pubitemid 28109549)
40. Clausen, A.; Xu, X.; Bi, X.; Baudry, M. Effects of the superoxide dismutase/catalase mimetic EUK-207 in a mouse model of Alzheimer's disease: protection against and interruption of progression of amyloid and tau pathology and cognitive decline. J. Alzheimers Dis. 30: 183-208; 2012.
41. Mao, P.; Manczak, M.; Calkins, M. J.; Truong, Q.; Reddy, T. P.; Reddy, A. P., et al. Mitochondria-targeted catalase reduces abnormal APP processing, amyloid beta production and BACE1 in a mouse model of Alzheimer's disease: implications for neuroprotection and lifespan extension. Hum. Mol. Genet. 21: 2973-2990; 2012.
42. Klivenyi, P.; Andreassen, O. A.; Ferrante, R. J.; Dedeoglu, A.; Mueller, G.; Lancelot, E., et al. Mice deficient in cellular glutathione peroxidase show increased vulnerability to malonate, 3-nitropropionic acid, and 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. J. Neurosci. 20: 1-7; 2000. (Pubitemid 30220485)
43. Arner, E. S.; Holmgren, A. Physiological functions of thioredoxin and thioredoxin reductase. Eur. J. Biochem. 267: 6102-6109; 2000.
44. Hori, K.; Katayama, M.; Sato, N.; Ishii, K.; Waga, S.; Yodoi, J. Neuroprotection by glial cells through adult T cell leukemia-derived factor/human thior-edoxin (ADF/TRX). Brain Res. 652: 304-310; 1994. (Pubitemid 24227286)
45. Umeda-Kameyama, Y.; Tsuda, M.; Ohkura, C.; Matsuo, T.; Namba, Y.; Ohuchi, Y., et al. Thioredoxin suppresses Parkin-associated endothelin receptor-like receptor-induced neurotoxicity and extends longevity in Drosophila. J. Biol. Chem. 282: 11180-11187; 2007. (Pubitemid 47100768)
46. Wood, Z. A.; Schroder, E.; Robin, H. J.; Poole, L. B. Structure, mechanism and regulation of peroxiredoxins. Trends Biochem. Sci. 28: 32-40; 2003.
47. Gan, Y.; Ji, X.; Hu, X.; Luo, Y.; Zhang, L.; Li, P., et al. Transgenic over-expression of peroxiredoxin-2 attenuates ischemic neuronal injury via suppression of a redox-sensitive pro-death signaling pathway. Antioxid. Redox Signaling 17: 719-732; 2012.
48. Hu, X.; Weng, Z.; Chu, C. T.; Zhang, L.; Cao, G.; Gao, Y., et al. Peroxiredoxin-2 protects against 6-hydroxydopamine-induced dopaminergic neurodegen-eration via attenuation of the apoptosis signal-regulating kinase (ASK1) signaling cascade. J. Neurosci. 31: 247-261; 2011.
49. Uttara, B.; Singh, A. V.; Zamboni, P.; Mahajan, R. T. Oxidative stress and neurodegenerative diseases: a review of upstream and downstream anti-oxidant therapeutic options. Curr. Neuropharmacol. 7: 65-74; 2009.
50. Pompella, A.; Visvikis, A.; Paolicchi, A.; De Tata, V.; Casini, A. F. The changing faces of glutathione, a cellular protagonist. Biochem. Pharmacol. 66: 1499-1503; 2003. (Pubitemid 38373339)
51. Lee, M.; Cho, T.; Jantaratnotai, N.; Wang, Y. T.; McGeer, E.; McGeer, P. L. Depletion of GSH in glial cells induces neurotoxicity: relevance to aging and degenerative neurological diseases. FASEB J. 24: 2533-2545; 2010.
52. Aiguo, W.; Zhe, Y.; Gomez-Pinilla, F. Vitamin E protects against oxidative damage and learning disability after mild traumatic brain injury in rats. Neurorehabil. Neural Repair 24: 290-298; 2010.
53. Conte, V.; Uryu, K.; Fujimoto, S.; Yao, Y.; Rokach, J.; Longhi, L., et al. Vitamin E reduces amyloidosis and improves cognitive function in Tg2576 mice following repetitive concussive brain injury. J. Neurochem. 90: 758-764; 2004. (Pubitemid 38989408)
54. Ienco, E. C.; LoGerfo, A.; Carlesi, C.; Orsucci, D.; Ricci, G.; Mancuso, M., et al. Oxidative stress treatment for clinical trials in neurodegenerative diseases. J. Alzheimers Dis. 24(Suppl. 2): 111-126; 2011.
55. Martin, A.; Youdim, K.; Szprengiel, A.; Shukitt-Hale, B.; Joseph, J. Roles of vitamins E and C on neurodegenerative diseases and cognitive performance. Nutr. Rev. 60: 308-326; 2002.
56. Hyson, H. C.; Kieburtz, K.; Shoulson, I.; McDermott, M.; Ravina, B.; de Blieck, E. A., et al. Safety and tolerability of high-dosage coenzyme Q10 in Huntington's disease and healthy subjects. Mov. Disord. 25: 1924-1928; 2010.
57. Shults, C. W.; Oakes, D.; Kieburtz, K.; Beal, M. F.; Haas, R.; Plumb, S., et al. Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. Arch. Neurol. 59: 1541-1550; 2002.
58. Shringarpure, R.; Grune, T.; Davies, K. J. Protein oxidation and 20S proteasome-dependent proteolysis in mammalian cells. Cell Mol. Life Sci. 58: 1442-1450; 2001. (Pubitemid 32964414)
59. Coux, O.; Tanaka, K.; Goldberg, A. L. Structure and functions of the 20S and 26S proteasomes. Annu. Rev. Biochem. 65: 801-847; 1996. (Pubitemid 26255262)
60. Hershko, A.; Ciechanover, A. The ubiquitin system. Annu. Rev. Biochem. 67: 425-479; 1998. (Pubitemid 28411135)
61. Cuervo, A. M. Autophagy: many paths to the same end. Mol. Cell. Biochem. 263: 55-72; 2004. (Pubitemid 39256145)
62. Reggiori, F.; Klionsky, D. J. Autophagy in the eukaryotic cell. Eukaryotic Cell 1: 11-21; 2002. (Pubitemid 36562345)
63. Wang, C. W.; Klionsky, D. J. The molecular mechanism of autophagy. Mol. Med. 9: 65-76; 2003. (Pubitemid 36819962)
64. Bader, N.; Jung, T.; Grune, T. The proteasome and its role in nuclear protein maintenance. Exp. Gerontol. 42: 864-870; 2007. (Pubitemid 47268733)
65. Chen, P.; Hochstrasser, M. Autocatalytic subunit processing couples active site formation in the 20S proteasome to completion of assembly. Cell 86: 961-972; 1996. (Pubitemid 26336800)
66. Peters, J. M.; Franke, W. W.; Kleinschmidt, J. A. Distinct 19 S and 20 S subcomplexes of the 26 S proteasome and their distribution in the nucleus and the cytoplasm. J. Biol. Chem. 269: 7709-7718; 1994. (Pubitemid 24217985)
67. Hilt, W.; Heinemeyer, W.; Wolf, D. H. Studies on the yeast proteasome uncover its basic structural features and multiple in vivo functions. Enzyme Protein 47: 189-201; 1993.
68. Bingol, B.; Sheng, M. Deconstruction for reconstruction: the role of proteo-lysis in neural plasticity and disease. Neuron 69: 22-32; 2011.
69. Schwarz, L. A.; Patrick, G. N. Ubiquitin-dependent endocytosis, trafficking and turnover of neuronal membrane proteins. Mol. Cell. Neurosci. 49: 387-393; 2012.
70. Morris, J. R.; Solomon, E. BRCA1:BARD1 induces the formation of conjugated ubiquitin structures, dependent on K6 of ubiquitin, in cells during DNA replication and repair. Hum. Mol. Genet. 13: 807-817; 2004. (Pubitemid 38515210)
71. Bowerman, B.; Kurz, T. Degrade to create: developmental requirements for ubiquitin-mediated proteolysis during early C. elegans embryogenesis. Development 133: 773-784; 2006.
72. Schnell, J. D.; Hicke, L. Non-traditional functions of ubiquitin and ubiquitin-binding proteins. J. Biol. Chem. 278: 35857-35860; 2003. (Pubitemid 37139902)
73. Collins, G. A.; Tansey, W. P. The proteasome: a utility tool for transcription? Curr. Opin. Genet. Dev 16: 197-202; 2006. (Pubitemid 43376068)
74. Lipford, J. R.; Deshaies, R. J. Diverse roles for ubiquitin-dependent proteo-lysis in transcriptional activation. Nat. Cell Biol. 5: 845-850; 2003. (Pubitemid 37220683)
75. Dynek, J. N.; Goncharov, T.; Dueber, E. C.; Fedorova, A. V.; Izrael-Tomasevic, A.; Phu, L., et al. c-IAP1 and UbcH5 promote K11-linked polyubiquitination of RIP1 in TNF signalling. EMBO J. 29: 4198-4209; 2010.
76. Grune, T.; Reinheckel, T.; Davies, K. J. Degradation of oxidized proteins in mammalian cells. FASEB J. 11: 526-534; 1997. (Pubitemid 27274426)
77. Poppek, D.; Grune, T. Proteasomal defense of oxidative protein modifications. Antioxid. Redox Signaling 8: 173-184; 2006. (Pubitemid 43324544)
78. Rock, K. L.; Gramm, C.; Rothstein, L.; Clark, K.; Stein, R.; Dick, L., et al. Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules. Cell 78: 761-771; 1994. (Pubitemid 24294452)
79. Wang, J.; Maldonado, M. A. The ubiquitin-proteasome system and its role in inflammatory and autoimmune diseases. Cell. Mol. Immunol. 3: 255-261; 2006.
80. Xiao, B. G.; Link, H. Immune regulation within the central nervous system. J. Neurol. Sci. 157: 1-12; 1998. (Pubitemid 28179529)
81. Dahlmann, B.; Kuehn, L. The 20S/26S proteasomal pathway of protein degradation in muscle tissue. Mol. Biol. Rep. 21: 57-62; 1995.
82. Hilt, W.; Wolf, D. H. Proteasomes: destruction as a programme. Trends Biochem. Sci. 21: 96-102; 1996. (Pubitemid 26085981)
83. Baumeister, W.; Walz, J.; Zuhl, F.; Seemuller, E. The proteasome: paradigm of a self-compartmentalizing protease. Cell 92: 367-380; 1998. (Pubitemid 28093014)
84. Dick, T. P.; Nussbaum, A. K.; Deeg, M.; Heinemeyer, W.; Groll, M.; Schirle, M., et al. Contribution of proteasomal beta-subunits to the cleavage of peptide substrates analyzed with yeast mutants. J. Biol. Chem. 273: 25637-25646; 1998. (Pubitemid 28475784)
85. Groll, M.; Ditzel, L.; Lowe, J.; Stock, D.; Bochtler, M.; Bartunik, H. D., et al. Structure of 20S proteasome from yeast at 2.4 A resolution. Nature 386: 463-471; 1997. (Pubitemid 27164066)
86. Davies, K. J. Degradation of oxidized proteins by the 20S proteasome. Biochimie 83: 301-310; 2001. (Pubitemid 32293650)
87. Friguet, B.; Bulteau, A. L.; Chondrogianni, N.; Conconi, M.; Petropoulos, I. Protein degradation by the proteasome and its implications in aging. Ann. N. Y. Acad. Sci. 908: 143-154; 2000. (Pubitemid 30462000)
88. Grune, T.; Reinheckel, T.; Davies, K. J. Degradation of oxidized proteins in K562 human hematopoietic cells by proteasome. J. Biol. Chem. 271: 15504-15509; 1996. (Pubitemid 26225322)
89. Rivett, A. J.; Mason, G. G.; Thomson, S.; Pike, A. M.; Savory, P. J.; Murray, R. Z. Catalytic components of proteasomes and the regulation of proteinase activity. Mol. Biol. Rep. 21: 35-41; 1995.
90. Shringarpure, R.; Grune, T.; Mehlhase, J.; Davies, K. J. Ubiquitin conjugation is not required for the degradation of oxidized proteins by proteasome. J. Biol. Chem. 278: 311-318; 2003. (Pubitemid 36043578)
91. Dou, H.; Huang, C.; Singh, M.; Carpenter, P. B.; Yeh, E. T. Regulation of DNA repair through deSUMOylation and SUMOylation of replication protein A complex. Mol. Cell 39: 333-345; 2010.
92. Wilkinson, K. A.; Henley, J. M. Mechanisms, regulation and consequences of protein SUMOylation. Biochem. J. 428: 133-145; 2010.
93. Mizushima, N.; Sugita, H.; Yoshimori, T.; Ohsumi, Y. A new protein conjugation system in human: the counterpart of the yeast Apg12p conjugation system essential for autophagy. J. Biol. Chem. 273: 33889-33892; 1998. (Pubitemid 29008848)
94. Aiken, C. T.; Kaake, R. M.; Wang, X.; Huang, L. Oxidative stress-mediated regulation of proteasome complexes. Mol. Cell. Proteomics 10(R110): 006924; 2011.
95. Ciechanover, A.; Brundin, P. The ubiquitin proteasome system in neurode-generative diseases: sometimes the chicken, sometimes the egg. Neuron 40: 427-446; 2003. (Pubitemid 37244106)
96. Ross, C. A.; Poirier, M. A. Protein aggregation and neurodegenerative disease. Nat. Med. 10(Suppl):S10-S17; 2004. (Pubitemid 38901862)
97. Bulteau, A. L.; Lundberg, K. C.; Humphries, K. M.; Sadek, H. A.; Szweda, P. A.; Friguet, B., et al. Oxidative modification and inactivation of the proteasome during coronary occlusion/reperfusion. J. Biol. Chem. 276: 30057-30063; 2001.
98. Demasi, M.; Shringarpure, R.; Davies, K. J. Glutathiolation of the proteasome is enhanced by proteolytic inhibitors. Arch. Biochem. Biophys. 389: 254-263; 2001. (Pubitemid 32881951)
99. Farout, L.; Mary, J.; Vinh, J.; Szweda, L. I.; Friguet, B. Inactivation of the proteasome by 4-hydroxy-2-nonenal is site specific and dependent on 20S proteasome subtypes. Arch. Biochem. Biophys 453: 135-142; 2006.
100. Ishii, T.; Sakurai, T.; Usami, H.; Uchida, K. Oxidative modification of proteasome: identification of an oxidation-sensitive subunit in 26 S protea-some. Biochemistry 44: 13893-13901; 2005. (Pubitemid 41507469)
101. Yao, D.; Gu, Z.; Nakamura, T.; Shi, Z. Q.; Ma, Y.; Gaston, B., et al. Nitrosative stress linked to sporadic Parkinson's disease: S-nitrosylation of parkin regulates its E3 ubiquitin ligase activity. Proc. Natl. Acad. Sci. USA 101: 10810-10814; 2004. (Pubitemid 38955824)
102. Shringarpure, R.; Grune, T.; Sitte, N.; Davies, K. J. 4-Hydroxynonenal-modified amyloid-beta peptide inhibits the proteasome: possible importance in Alzheimer's disease. Cell. Mol. Life Sci. 57: 1802-1809; 2000.
103. Ding, Q.; Reinacker, K.; Dimayuga, E.; Nukala, V.; Drake, J.; Butterfield, D. A., et al. Role of the proteasome in protein oxidation and neural viability following low-level oxidative stress. FEBS Lett. 546: 228-232; 2003. (Pubitemid 36782416)
104. Bulteau, A. L.; Petropoulos, I.; Friguet, B. Age-related alterations of proteasome structure and function in aging epidermis. Exp. Gerontol. 35: 767-777; 2000.
105. Bulteau, A. L.; Szweda, L. I.; Friguet, B. Age-dependent declines in protea-some activity in the heart. Arch. Biochem. Biophys. 397: 298-304; 2002. (Pubitemid 34852295)
106. Conconi, M.; Szweda, L. I.; Levine, R. L.; Stadtman, E. R.; Friguet, B. Age-related decline of rat liver multicatalytic proteinase activity and protection from oxidative inactivation by heat-shock protein 90. Arch. Biochem. Biophys. 331: 232-240; 1996. (Pubitemid 26256072)
107. Dasuri, K.; Zhang, L.; Ebenezer, P.; Liu, Y.; Fernandez-Kim, S. O.; Keller, J. N. Aging and dietary restriction alter proteasome biogenesis and composition in the brain and liver. Mech. Ageing Dev. 130: 777-783; 2009.
108. Dasuri, K.; Nguyen, A.; Zhang, L.; Fernandez-Kim, O. S.; Bruce-Keller, A. J.; Blalock, B. A., et al. Comparison of rat liver and brain proteasomes for oxidative stress-induced inactivation: influence of ageing and dietary restriction. Free Radic. Res. 43: 28-36; 2009.
109. Husom, A. D.; Peters, E. A.; Kolling, E. A.; Fugere, N. A.; Thompson, L. V.; Ferrington, D. A. Altered proteasome function and subunit composition in aged muscle. Arch. Biochem. Biophys. 421: 67-76; 2004. (Pubitemid 37543497)
110. Kapphahn, R. J.; Bigelow, E. J.; Ferrington, D. A. Age-dependent inhibition of proteasome chymotrypsin-like activity in the retina. Exp. Eye Res. 84: 646-654; 2007. (Pubitemid 46402984)
111. Keller, J. N.; Hanni, K. B.; Markesbery, W. R. Possible involvement of proteasome inhibition in aging: implications for oxidative stress. Mech. Ageing Dev. 113: 61-70; 2000. (Pubitemid 30050671)
112. Keller, J. N.; Huang, F. F.; Markesbery, W. R. Decreased levels of proteasome activity and proteasome expression in aging spinal cord. Neuroscience 98: 149-156; 2000. (Pubitemid 30349153)
113. Shibatani, T.; Nazir, M.; Ward, W. F. Alteration of rat liver 20S proteasome activities by age and food restriction. J. Gerontol. A Biol. Sci. Med. Sci. 51:B316-B322; 1996. (Pubitemid 26313654)
114. Tomaru, U.; Takahashi, S.; Ishizu, A.; Miyatake, Y.; Gohda, A.; Suzuki, S., et al. Decreased proteasomal activity causes age-related phenotypes and promotes the development of metabolic abnormalities. Am. J. Pathol. 180: 963-972; 2012.
115. Friguet, B.; Szweda, L. I. Inhibition of the multicatalytic proteinase (protea-some) by 4-hydroxy-2-nonenal cross-linked protein. FEBS Lett. 405: 21-25; 1997. (Pubitemid 27130365)
116. Jahngen-Hodge, J.; Obin, M. S.; Gong, X.; Shang, F.; Nowell Jr. T. R.; Gong, J., et al. Regulation of ubiquitin-conjugating enzymes by glutathione following oxidative stress. J. Biol. Chem. 272: 28218-28226; 1997. (Pubitemid 27517760)
117. Shang, F.; Taylor, A. Ubiquitin-proteasome pathway and cellular responses to oxidative stress. Free Radic. Biol. Med. 51: 5-16; 2011.
118. Grune, T.; Jung, T.; Merker, K.; Davies, K. J. Decreased proteolysis caused by protein aggregates, inclusion bodies, plaques, lipofuscin, ceroid, and 'aggre-somes' during oxidative stress, aging, and disease. Int. J. Biochem. Cell Biol. 36: 2519-2530; 2004. (Pubitemid 39119763)
119. Keller, J. N.; Hanni, K. B.; Markesbery, W. R. Impaired proteasome function in Alzheimer's disease. J. Neurochem. 75: 436-439; 2000. (Pubitemid 30418211)
120. Lopez, S. M.; Morelli, L.; Castano, E. M.; Soto, E. F.; Pasquini, J. M. Defective ubiquitination of cerebral proteins in Alzheimer's disease. J. Neurosci. Res. 62: 302-310; 2000.
121. Mori, H.; Kondo, J.; Ihara, Y. Ubiquitin is a component of paired helical filaments in Alzheimer's disease. Science 235: 1641-1644; 1987. (Pubitemid 17050146)
122. Perry, G.; Friedman, R.; Shaw, G.; Chau, V. Ubiquitin is detected in neurofibrillary tangles and senile plaque neurites of Alzheimer disease brains. Proc. Natl. Acad. Sci. USA 84: 3033-3036; 1987. (Pubitemid 17064772)
123. van Leeuwen, F. W.; de Kleijn, D. P.; van den Hurk, H. H.; Neubauer, A.; Sonnemans, M. A.; Sluijs, J. A., et al. Frameshift mutants of beta amyloid precursor protein and ubiquitin-B in Alzheimer's and Down patients. Science 279: 242-247; 1998. (Pubitemid 28103884)
124. Lindsten, K.; de Vrij, F. M.; Verhoef, L. G.; Fischer, D. F.; van Leeuwen, F. W.; Hol, E. M., et al. Mutant ubiquitin found in neurodegenerative disorders is a ubiquitin fusion degradation substrate that blocks proteasomal degradation. J. Cell Biol. 157: 417-427; 2002. (Pubitemid 34839806)
125. Castegna, A.; Thongboonkerd, V.; Klein, J. B.; Lynn, B.; Markesbery, W. R.; Butterfield, D. A. Proteomic identification of nitrated proteins in Alzheimer's disease brain. J. Neurochem. 85: 1394-1401; 2003. (Pubitemid 36702552)
126. Leroy, E.; Boyer, R.; Auburger, G.; Leube, B.; Ulm, G.; Mezey, E., et al. The ubiquitin pathway in Parkinson's disease. Nature 395: 451-452; 1998.
127. de Vrij, F. M.; Sluijs, J. A.; Gregori, L.; Fischer, D. F.; Hermens, W. T.; Goldgaber, D., et al. Mutant ubiquitin expressed in Alzheimer's disease causes neuronal death. FASEB J. 15: 2680-2688; 2001. (Pubitemid 33131094)
128. Song, S.; Kim, S. Y.; Hong, Y. M.; Jo, D. G.; Lee, J. Y.; Shim, S. M., et al. Essential role of E2-25K/Hip-2 in mediating amyloid-beta neurotoxicity. Mol. Cell 12: 553-563; 2003. (Pubitemid 37222479)
129. Ko, S.; Kang, G. B.; Song, S. M.; Lee, J. G.; Shin, D. Y.; Yun, J. H., et al. Structural basis of E2-25K/UBB+1 interaction leading to proteasome inhibition and neurotoxicity. J. Biol. Chem. 285: 36070-36080; 2010.
130. McNaught, K. S.; Belizaire, R.; Jenner, P.; Olanow, C. W.; Isacson, O. Selective loss of 20S proteasome alpha-subunits in the substantia nigra pars com-pacta in Parkinson's disease. Neurosci. Lett. 326: 155-158; 2002. (Pubitemid 34722448)
131. Sun, F.; Anantharam, V.; Zhang, D.; Latchoumycandane, C.; Kanthasamy, A.; Kanthasamy, A. G. Proteasome inhibitor MG-132 induces dopaminergic degeneration in cell culture and animal models. Neurotoxicology 27: 807-815; 2006. (Pubitemid 44232996)
132. Um, J. W.; Im, E.; Lee, H. J.; Min, B.; Yoo, L.; Yoo, J., et al. Parkin directly modulates 26S proteasome activity. J. Neurosci. 30: 11805-11814; 2010.
133. Bedford, L.; Hay, D.; Devoy, A.; Paine, S.; Powe, D. G.; Seth, R., et al. Depletion of 26S proteasomes in mouse brain neurons causes neurodegen-eration and Lewy-like inclusions resembling human pale bodies. J. Neurosci. 28: 8189-8198; 2008.
134. Chung, K. K.; Thomas, B.; Li, X.; Pletnikova, O.; Troncoso, J. C.; Marsh, L., et al. S-nitrosylation of parkin regulates ubiquitination and compromises parkin's protective function. Science 304: 1328-1331; 2004. (Pubitemid 38697430)
135. Choi, J.; Levey, A. I.; Weintraub, S. T.; Rees, H. D.; Gearing, M.; Chin, L. S., et al. Oxidative modifications and down-regulation of ubiquitin carboxyl-terminal hydrolase L1 associated with idiopathic Parkinson's and Alzheimer's diseases. J. Biol. Chem 279: 13256-13264; 2004. (Pubitemid 38445905)
136. Davies, S. W.; Scherzinger, E. Nuclear inclusions in Huntington's disease. Trends Cell Biol. 7: 422; 1997.
137. DiFiglia, M.; Sapp, E.; Chase, K. O.; Davies, S. W.; Bates, G. P.; Vonsattel, J. P., et al. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science 277: 1990-1993; 1997. (Pubitemid 27449140)
138. Jana, N. R.; Zemskov, E. A.; Wang, G.; Nukina, N. Altered proteasomal function due to the expression of polyglutamine-expanded truncated N-terminal huntingtin induces apoptosis by caspase activation through mitochondrial cytochrome c release. Hum. Mol. Genet. 10: 1049-1059; 2001. (Pubitemid 32447782)
139. Seo, H.; Sonntag, K. C.; Isacson, O. Generalized brain and skin proteasome inhibition in Huntington's disease. Ann. Neurol. 56: 319-328; 2004. (Pubitemid 39166550)
140. Browne, S. E.; Ferrante, R. J.; Beal, M. F. Oxidative stress in Huntington's disease. Brain Pathol. 9: 147-163; 1999. (Pubitemid 29056525)
141. Sadagurski, M.; Cheng, Z.; Rozzo, A.; Palazzolo, I.; Kelley, G. R.; Dong, X., et al. IRS2 increases mitochondrial dysfunction and oxidative stress in a mouse model of Huntington disease. J. Clin. Invest. 121: 4070-4081; 2011.
142. Johnson, J. O.; Mandrioli, J.; Benatar, M.; Abramzon, Y.; Van Deerlin, V. M.; Trojanowski, J. Q., et al. Exome sequencing reveals VCP mutations as a cause of familial ALS. Neuron 68: 857-864; 2010.
143. Kwiatkowski Jr. T. J.; Bosco, D. A.; Leclerc, A. L.; Tamrazian, E.; Vanderburg, C. R.; Russ, C., et al. Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science 323: 1205-1208; 2009.
144. Sreedharan, J.; Blair, I. P.; Tripathi, V. B.; Hu, X.; Vance, C.; Rogelj, B., et al. TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis. Science 319: 1668-1672; 2008. (Pubitemid 351432505)
145. Bendotti, C.; Marino, M.; Cheroni, C.; Fontana, E.; Crippa, V.; Poletti, A., et al. Dysfunction of constitutive and inducible ubiquitin-proteasome system in amyotrophic lateral sclerosis: implication for protein aggregation and immune response. Prog. Neurobiol. 97: 101-126; 2012.
146. Cheroni, C.; Peviani, M.; Cascio, P.; Debiasi, S.; Monti, C.; Bendotti, C. Accumulation of human SOD1 and ubiquitinated deposits in the spinal cord of SOD1G93A mice during motor neuron disease progression correlates with a decrease of proteasome. Neurobiol. Dis. 18: 509-522; 2005. (Pubitemid 40332710)
147. Leigh, P. N.; Whitwell, H.; Garofalo, O.; Buller, J.; Swash, M.; Martin, J. E., et al. Ubiquitin-immunoreactive intraneuronal inclusions in amyotrophic lateral sclerosis: morphology, distribution, and specificity. Brain 114(Pt 2): 775-788; 1991.
148. Urushitani, M.; Kurisu, J.; Tsukita, K.; Takahashi, R. Proteasomal inhibition by misfolded mutant superoxide dismutase 1 induces selective motor neuron death in familial amyotrophic lateral sclerosis. J. Neurochem. 83: 1030-1042; 2002. (Pubitemid 35397113)
149. Watanabe, M.; Dykes-Hoberg, M.; Culotta, V. C.; Price, D. L.; Wong, P. C.; Rothstein, J. D. Histological evidence of protein aggregation in mutant SOD1 transgenic mice and in amyotrophic lateral sclerosis neural tissues. Neuro-biol. Dis. 8: 933-941; 2001. (Pubitemid 34017087)
150. Cheroni, C.; Marino, M.; Tortarolo, M.; Veglianese, P.; De, B. S.; Fontana, E., et al. Functional alterations of the ubiquitin-proteasome system in motor neurons of a mouse model of familial amyotrophic lateral sclerosis. Hum. Mol. Genet. 18: 82-96; 2009.
151. Kabashi, E.; Agar, J. N.; Strong, M. J.; Durham, H. D. Impaired proteasome function in sporadic amyotrophic lateral sclerosis. Amyotrophic Lateral Scler. 13: 367-371; 2012.
152. van, E. J.; Ke, Y. D.; Gladbach, A.; Bi, M.; Gotz, J.; Kril, J. J., et al. Cytoplasmic accumulation and aggregation of TDP-43 upon proteasome inhibition in cultured neurons. PLoS One 6:e22850; 2011.
153. Poon, H. F.; Hensley, K.; Thongboonkerd, V.; Merchant, M. L.; Lynn, B. C.; Pierce, W. M., et al. Redox proteomics analysis of oxidatively modified proteins in G93A-SOD1 transgenic mice - a model of familial amyotrophic lateral sclerosis. Free Radic. Biol. Med. 39: 453-462; 2005. (Pubitemid 41021644)
154. Mattiazzi, M.; D'Aurelio, M.; Gajewski, C. D.; Martushova, K.; Kiaei, M.; Beal, M. F., et al. Mutated human SOD1 causes dysfunction of oxidative phosphorylation in mitochondria of transgenic mice. J. Biol. Chem. 277: 29626-29633; 2002. (Pubitemid 41079252)
155. Di, N. M.; McLaughlin, B. The ubiquitin-proteasome system as a drug target in cerebrovascular disease: therapeutic potential of proteasome inhibitors. Curr. Opin. Invest. Drugs 6: 686-699; 2005. (Pubitemid 40904039)
156. Meller, R. The role of the ubiquitin proteasome system in ischemia and ischemic tolerance. Neuroscientist 15: 243-260; 2009.
157. Wojcik, C.; Di, N. M. Ubiquitin-proteasome system and proteasome inhibition: new strategies in stroke therapy. Stroke 35: 1506-1518; 2004. (Pubitemid 38697484)
158. Keller, J. N.; Huang, F. F.; Zhu, H.; Yu, J.; Ho, Y. S.; Kindy, T. S. Oxidative stress-associated impairment of proteasome activity during ischemia- reperfusion injury. J. Cereb. Blood Flow Metab. 20: 1467-1473; 2000.
159. Asai, A.; Tanahashi, N.; Qiu, J. H.; Saito, N.; Chi, S.; Kawahara, N., et al. Selective proteasomal dysfunction in the hippocampal CA1 region after transient forebrain ischemia. J. Cereb. Blood Flow Metab. 22: 705-710; 2002. (Pubitemid 34596463)
160. Liu, C. L.; Martone, M. E.; Hu, B. R. Protein ubiquitination in postsynaptic densities after transient cerebral ischemia. J. Cereb. Blood Flow Metab. 24: 1219-1225; 2004. (Pubitemid 39482483)
161. Keller, J. N.; Kindy, M. S.; Holtsberg St F. W.; Clair, D. K.; Yen, H. C.; Germeyer, A., et al. Mitochondrial manganese superoxide dismutase prevents neural apoptosis and reduces ischemic brain injury: suppression of peroxynitrite production, lipid peroxidation, and mitochondrial dysfunction. J. Neurosci. 18: 687-697; 1998. (Pubitemid 28041905)
162. Ravikumar, B.; Sarkar, S.; Davies, J. E.; Futter, M.; Garcia-Arencibia, M.; Green-Thompson, Z. W., et al. Regulation of mammalian autophagy in physiology and pathophysiology. Physiol. Rev. 90: 1383-1435; 2010.
163. Cuervo, A. M. Chaperone-mediated autophagy: Dice's 'wild' idea about lysosomal selectivity. Nat. Rev. Mol. Cell Biol. 12: 535-541; 2011.
164. Keller, J. N.; Dimayuga, E.; Chen, Q.; Thorpe, J.; Gee, J.; Autophagy, Ding Q. proteasomes, lipofuscin, and oxidative stress in the aging brain. Int. J. Biochem. Cell Biol. 36: 2376-2391; 2004. (Pubitemid 39119753)
165. Levine, B.; Kroemer, G. Autophagy in the pathogenesis of disease. Cell 132: 27-42; 2008.
166. Ding, Q.; Dimayuga, E.; Martin, S.; Bruce-Keller, A. J.; Nukala, V.; Cuervo, A. M., et al. Characterization of chronic low-level proteasome inhibition on neural homeostasis. J. Neurochem 86: 489-497; 2003. (Pubitemid 36842448)
167. Sullivan, P. G.; Dragicevic, N. B.; Deng, J. H.; Bai, Y.; Dimayuga, E.; Ding, Q., et al. Proteasome inhibition alters neural mitochondrial homeostasis and mitochondria turnover. J. Biol. Chem. 279: 20699-20707; 2004. (Pubitemid 38656466)
168. Kiffin, R.; Christian, C.; Knecht, E.; Cuervo, A. M. Activation of chaperone-mediated autophagy during oxidative stress. Mol. Biol. Cell 15: 4829-4840; 2004. (Pubitemid 39392200)
169. Lemasters, J. J. Selective mitochondrial autophagy, or mitophagy, as a targeted defense against oxidative stress, mitochondrial dysfunction, and aging. Rejuvenation Res. 8: 3-5; 2005.
170. Lee, J.; Giordano, S.; Autophagy, Zhang J. mitochondria and oxidative stress: cross-talk and redox signalling. Biochem. J. 441: 523-540; 2012.
171. Nixon, R. A. Autophagy in neurodegenerative disease: friend, foe or turncoat? Trends Neurosci 29: 528-535; 2006. (Pubitemid 44291816)
172. Pivtoraiko, V. N.; Stone, S. L.; Roth, K. A.; Shacka, J. J. Oxidative stress and autophagy in the regulation of lysosome-dependent neuron death. Antioxid. Redox Signaling 11: 481-496; 2009.
173. Caballero, B.; Coto-Montes, A. An insight into the role of autophagy in cell responses in the aging and neurodegenerative brain. Histol. Histopathol. 27: 263-275; 2012.
174. Cuervo, A. M. Autophagy and aging: keeping that old broom working. Trends Genet. 24: 604-612; 2008.
175. Cuervo, A. M. The plasma membrane brings autophagosomes to life. Nat. Cell Biol. 12: 735-737; 2010.
176. Oenzil, F.; Kishikawa, M.; Mizuno, T.; Nakano, M. Age-related accumulation of lipofuscin in three different regions of rat brain. Mech. Ageing Dev. 76: 157-163; 1994. (Pubitemid 24326361)
177. Cataldo, A. M.; Paskevich, P. A.; Kominami, E.; Nixon, R. A. Lysosomal hydrolases of different classes are abnormally distributed in brains of patients with Alzheimer disease. Proc. Natl. Acad. Sci. USA 88: 10998-11002; 1991. (Pubitemid 21915966)
178. Lynch, G.; Bi, X. Lysosomes and brain aging in mammals. Neurochem. Res. 28: 1725-1734; 2003. (Pubitemid 37296214)
179. Hara, T.; Nakamura, K.; Matsui, M.; Yamamoto, A.; Nakahara, Y.; Suzuki-Migishima, R., et al. Suppression of basal autophagy in neural cells causes neurodegenerative disease in mice. Nature 441: 885-889; 2006.
180. Komatsu, M.; Kominami, E.; Tanaka, K. Autophagy and neurodegeneration. Autophagy 2: 315-317; 2006. (Pubitemid 44342380)
181. Yu, W. H.; Cuervo, A. M.; Kumar, A.; Peterhoff, C. M.; Schmidt, S. D.; Lee, J. H., et al. Macroautophagy - a novel beta-amyloid peptide-generating pathway activated in Alzheimer's disease. J. Cell Biol. 171: 87-98; 2005. (Pubitemid 41434604)
182. Pickford, F.; Masliah, E.; Britschgi, M.; Lucin, K.; Narasimhan, R.; Jaeger, P. A., et al. The autophagy-related protein beclin 1 shows reduced expression in early Alzheimer disease and regulates amyloid beta accumulation in mice. J. Clin. Invest. 118: 2190-2199; 2008. (Pubitemid 351872337)
183. Lee, J. H.; Yu, W. H.; Kumar, A.; Lee, S.; Mohan, P. S.; Peterhoff, C. M., et al. Lysosomal proteolysis and autophagy require presenilin 1 and are disrupted by Alzheimer-related PS1 mutations. Cell 141: 1146-1158; 2010.
184. Zheng, L.; Terman, A.; Hallbeck, M.; Dehvari, N.; Cowburn, R. F.; Benedikz, E., et al. Macroautophagy-generated increase of lysosomal amyloid beta-protein mediates oxidant-induced apoptosis of cultured neuroblastoma cells. Autophagy 7: 1528-1545; 2011.
185. Cook, C.; Stetler, C.; Petrucelli, L. Disruption of protein quality control in Parkinson's disease. Cold Spring Harbor Perspect. Med. 2; 2012a009423 2; 2012.
186. Vogiatzi, T.; Xilouri, M.; Vekrellis, K.; Stefanis, L. Wild type alpha-synuclein is degraded by chaperone-mediated autophagy and macroautophagy in neuronal cells. J. Biol. Chem. 283; 2008. 23542-23556.
187. Qiao, L.; Hamamichi, S.; Caldwell, K. A.; Caldwell, G. A.; Yacoubian, T. A.; Wilson, S., et al. Lysosomal enzyme cathepsin D protects against alpha-synuclein aggregation and toxicity. Mol. Brain. 1: 17; 2008.
188. Nakanishi, H.; Zhang, J.; Koike, M.; Nishioku, T.; Okamoto, Y.; Kominami, E., et al. Involvement of nitric oxide released from microglia-macrophages in pathological changes of cathepsin D-deficient mice. J. Neurosci. 21: 7526-7533; 2001. (Pubitemid 32904951)
189. Gusdon, A. M.; Zhu, J.; Van, H. B.; Chu, C. T. ATP13A2 regulates mitochondrial bioenergetics through macroautophagy. Neurobiol. Dis. 45: 962-972; 2012.
190. Narendra, D.; Tanaka, A.; Suen, D. F.; Youle, R. J. Parkin is recruited selectively to impaired mitochondria and promotes their autophagy. J. Cell Biol. 183: 795-803; 2008.
191. Wang, Y.; Nartiss, Y.; Steipe, B.; McQuibban, G. A.; Kim, P. K. ROS-induced mitochondrial depolarization initiates PARK2/PARKIN-dependent mito-chondrial degradation by autophagy. Autophagy 8; 2012.
192. Sapp, E.; Schwarz, C.; Chase, K.; Bhide, P. G.; Young, A. B.; Penney, J., et al. Huntingtin localization in brains of normal and Huntington's disease patients. Ann. Neurol. 42: 604-612; 1997. (Pubitemid 27439023)
193. Bence, N. F.; Sampat, R. M.; Kopito, R. R. Impairment of the ubiquitin- proteasome system by protein aggregation. Science 292: 1552-1555; 2001. (Pubitemid 32493425)
194. Hetz, C.; Thielen, P.; Matus, S.; Nassif, M.; Court, F.; Kiffin, R., et al. XBP-1 deficiency in the nervous system protects against amyotrophic lateral sclerosis by increasing autophagy. Genes Dev. 23: 2294-2306; 2009.
195. Sasaki, S. Autophagy in spinal cord motor neurons in sporadic amyotrophic lateral sclerosis. J. Neuropathol. Exp. Neurol. 70: 349-359; 2011.
196. Li, L.; Zhang, X.; Le, W. Altered macroautophagy in the spinal cord of SOD1 mutant mice. Autophagy 4: 290-293; 2008. (Pubitemid 351458089)
197. Wootz, H.; Weber, E.; Korhonen, L.; Lindholm, D. Altered distribution and levels of cathepsinD and cystatins in amyotrophic lateral sclerosis trans-genic mice: possible roles in motor neuron survival. Neuroscience 143: 419-430; 2006. (Pubitemid 44781062)
198. Adhami, F.; Liao, G.; Morozov, Y. M.; Schloemer, A.; Schmithorst, V. J.; Lorenz, J. N., et al. Cerebral ischemia-hypoxia induces intravascular coagulation and autophagy. Am. J. Pathol. 169: 566-583; 2006. (Pubitemid 44156315)
199. Ginet, V.; Puyal, J.; Clarke, P. G.; Truttmann, A. C. Enhancement of autophagic flux after neonatal cerebral hypoxia-ischemia and its region-specific relationship to apoptotic mechanisms. Am. J. Pathol. 175: 1962-1974; 2009.
200. Koike, M.; Shibata, M.; Tadakoshi, M.; Gotoh, K.; Komatsu, M.; Waguri, S., et al. Inhibition of autophagy prevents hippocampal pyramidal neuron death after hypoxic-ischemic injury. Am. J. Pathol. 172: 454-469; 2008. (Pubitemid 351282032)
201. Zheng, C.; Han, J.; Xia, W.; Shi, S.; Liu, J.; Ying, W. NAD(+) administration decreases ischemic brain damage partially by blocking autophagy in a mouse model of brain ischemia. Neurosci. Lett. 512: 67-71; 2012.
202. Nagase, H.; Woessner Jr. J. F. Matrix metalloproteinases. J. Biol. Chem. 274: 21491-21494; 1999.
203. Hartung, H. P.; Kieseier, B. C. The role of matrix metalloproteinases in autoimmune damage to the central and peripheral nervous system. J. Neuroimmunol. 107: 140-147; 2000. (Pubitemid 30347419)
204. Lukashev, M. E.; Werb, Z. ECM signalling: orchestrating cell behaviour and misbehaviour. Trends Cell Biol. 8: 437-441; 1998. (Pubitemid 28529716)
205. Muir, E. M.; Adcock, K. H.; Morgenstern, D. A.; Clayton, R.; von, S. N.; Rhodes, K., et al. Matrix metalloproteases and their inhibitors are produced by overlapping populations of activated astrocytes. Brain Res. Mol. Brain Res. 100: 103-117; 2002. (Pubitemid 34465583)
206. Deb, S.; Gottschall, P. E. Increased production of matrix metalloproteinases in enriched astrocyte and mixed hippocampal cultures treated with beta-amyloid peptides. J. Neurochem. 66: 1641-1647; 1996. (Pubitemid 26090566)
207. Deb, S.; Wenjun, Z. J.; Gottschall, P. E. Beta-amyloid induces the production of active, matrix-degrading proteases in cultured rat astrocytes. Brain Res. 970: 205-213; 2003. (Pubitemid 36423196)
208. Backstrom, J. R.; Lim, G. P.; Cullen, M. J.; Tokes, Z. A. Matrix metalloproteinase-9 (MMP-9) is synthesized in neurons of the human hippocampus and is capable of degrading the amyloid-beta peptide (1-40). J. Neurosci. 16: 7910-7919; 1996. (Pubitemid 26405054)
209. LePage, R. N.; Fosang, A. J.; Fuller, S. J.; Murphy, G.; Evin, G.; Beyreuther, K., et al. Gelatinase A possesses a beta-secretase-like activity in cleaving the amyloid protein precursor of Alzheimer's disease. FEBS Lett. 377: 267-270; 1995.
210. Walker, E. J.; TIMP-3, Rosenberg G. A. and MMP-3 contribute to delayed inflammation and hippocampal neuronal death following global ischemia. Exp. Neurol. 216: 122-131; 2009.
211. Chang, D. I.; Hosomi, N.; Lucero, J.; Heo, J. H.; Abumiya, T.; Mazar, A. P., et al. Activation systems for latent matrix metalloproteinase-2 are upregulated immediately after focal cerebral ischemia. J. Cereb. Blood Flow Metab. 23: 1408-1419; 2003. (Pubitemid 38018259)
212. Gasche, Y.; Copin, J. C.; Sugawara, T.; Fujimura, M.; Chan, P. H. Matrix metalloproteinase inhibition prevents oxidative stress-associated blood- brain barrier disruption after transient focal cerebral ischemia. J. Cereb. Blood Flow Metab. 21: 1393-1400; 2001. (Pubitemid 33120943)
213. Romanic, A. M.; White, R. F.; Arleth, A. J.; Ohlstein, E. H.; Barone, F. C. Matrix metalloproteinase expression increases after cerebral focal ischemia in rats: inhibition of matrix metalloproteinase-9 reduces infarct size. Stroke 29: 1020-1030; 1998. (Pubitemid 28228167)
214. Rosenberg, G. A.; Cunningham, L. A.; Wallace, J.; Alexander, S.; Estrada, E. Y.; Grossetete, M., et al. Immunohistochemistry of matrix metalloproteinases in reperfusion injury to rat brain: activation of MMP-9 linked to stromelysin-1 and microglia in cell cultures. Brain Res. 893: 104-112; 2001. (Pubitemid 32171902)
215. Rosenberg, G. A.; Navratil, M. Metalloproteinase inhibition blocks edema in intracerebral hemorrhage in the rat. Neurology 48: 921-926; 1997.
216. Sumii, T.; Lo, E. H. Involvement of matrix metalloproteinase in thrombolysis-associated hemorrhagic transformation after embolic focal ischemia in rats. Stroke 33: 831-836; 2002. (Pubitemid 34204013)
217. Ferguson, T. A.; Muir, D. MMP-2 and MMP-9 increase the neurite-promoting potential of Schwann cell basal laminae and are upregulated in degenerated nerve. Mol. Cell. Neurosci. 16: 157-167; 2000. (Pubitemid 30651178)
218. Vecil, G. G.; Larsen, P. H.; Corley, S. M.; Herx, L. M.; Besson, A.; Goodyer, C. G., et al. Interleukin-1 is a key regulator of matrix metalloproteinase-9 expression in human neurons in culture and following mouse brain trauma in vivo. J. Neurosci. Res 61: 212-224; 2000. (Pubitemid 30451809)
219. Nelson, K. K.; Melendez, J. A. Mitochondrial redox control of matrix metalloproteinases. Free Radic. Biol. Med. 37: 768-784; 2004. (Pubitemid 39078549)
220. Kim, E. M.; Shin, E. J.; Choi, J. H.; Son, H. J.; Park, I. S.; Joh, T. H., et al. Matrix metalloproteinase-3 is increased and participates in neuronal apoptotic signaling downstream of caspase-12 during endoplasmic reticulum stress. J. Biol. Chem 285: 16444-16452; 2010.
221. Kim, E. M.; Hwang, O. Role of matrix metalloproteinase-3 in neurodegen-eration. J. Neurochem. 116: 22-32; 2011.
222. Goll, D. E.; Thompson, V. F.; Li, H.; Wei, W.; Cong, J. The calpain system. Physiol. Rev. 83: 731-801; 2003. (Pubitemid 36828925)
223. Bezprozvanny, I. Calcium signaling and neurodegenerative diseases. Trends Mol. Med. 15: 89-100; 2009.
224. Goll, D. E.; Thompson, V. F.; Li, H.; Wei, W.; Cong, J. The calpain system. Physiol. Rev. 83: 731-801; 2003. (Pubitemid 36828925)
225. Saito, K.; Elce, J. S.; Hamos, J. E.; Nixon, R. A. Widespread activation of calcium-activated neutral proteinase (calpain) in the brain in Alzheimer disease: a potential molecular basis for neuronal degeneration. Proc. Natl. Acad. Sci. USA 90: 2628-2632; 1993. (Pubitemid 23113469)
226. Mouatt-Prigent, A.; Karlsson, J. O.; Agid, Y.; Hirsch, E. C. Increased M-calpain expression in the mesencephalon of patients with Parkinson's disease but not in other neurodegenerative disorders involving the mesencephalon: a role in nerve cell death? Neuroscience 73: 979-987; 1996.
227. Gafni, J.; Hermel, E.; Young, J. E.; Wellington, C. L.; Hayden, M. R.; Ellerby, L. M. Inhibition of calpain cleavage of huntingtin reduces toxicity: accumulation of calpain/caspase fragments in the nucleus. J. Biol. Chem. 279: 20211-20220; 2004. (Pubitemid 38623466)
228. Crocker, S. J.; Smith, P. D.; Jackson-Lewis, V.; Lamba, W. R. Hayley S.P., Grimm E., et al. Inhibition of calpains prevents neuronal and behavioral deficits in an MPTP mouse model of Parkinson's disease. J. Neurosci. 23: 4081-4091; 2003. (Pubitemid 36958427)
229. Kann, O.; Kovacs, R. Mitochondria and neuronal activity. Am. J. Physiol. Cell Physiol. 292:C641-C657; 2007.
230. Dykens, J. A. Isolated cerebral and cerebellar mitochondria produce free radicals when exposed to elevated Ca2+ and Na+: implications for neuro-degeneration. J. Neurochem. 63: 584-591; 1994.
231. Marcum, J. L.; Mathenia, J. K.; Chan, R.; Guttmann, R. P. Oxidation of thiol-proteases in the hippocampus of Alzheimer's disease. Biochem. Biophys. Res. Commun. 334: 342-348; 2005. (Pubitemid 40984028)
232. Ray, S. K.; Fidan, M.; Nowak, M. W.; Wilford, G. G.; Hogan, E. L.; Banik, N. L. Oxidative stress and Ca2+ influx upregulate calpain and induce apoptosis in PC12 cells. Brain Res. 852: 326-334; 2000. (Pubitemid 30035169)
233. Yamada, K. H.; Kozlowski, D. A.; Seidl, S. E.; Lance, S.; Wieschhaus, A. J.; Sundivakkam, P., et al. Targeted gene inactivation of calpain-1 suppresses cortical degeneration due to traumatic brain injury and neuronal apoptosis induced by oxidative stress. J. Biol. Chem. 287: 13182-13193; 2012.
234. Marcillat, O.; Zhang, Y.; Lin, S. W.; Davies, K. J. Mitochondria contain a proteolytic system which can recognize and degrade oxidatively-denatured proteins. Biochem. J. 254: 677-683; 1988.
235. Kaser, M.; Langer, T. Protein degradation in mitochondria. Semin. Cell Dev. Biol. 11: 181-190; 2000. (Pubitemid 32095011)
236. Bota, D. A.; Davies, K. J. Lon protease preferentially degrades oxidized mitochondrial aconitase by an ATP-stimulated mechanism. Nat. Cell Biol. 4: 674-680; 2002. (Pubitemid 34993703)
237. Major, T.; von, J. B.; Ruppert, T.; Mogk, A.; Voos, W. Proteomic analysis of mitochondrial protein turnover: identification of novel substrate proteins of the matrix protease pim1. Mol. Cell. Biol. 26: 762-776; 2006. (Pubitemid 43146474)
238. Bota, D. A.; Davies, K. J. Protein degradation in mitochondria: implications for oxidative stress, aging and disease: a novel etiological classification of mitochondrial proteolytic disorders. Mitochondrion 1: 33-49; 2001. (Pubitemid 33586019)
239. Bulteau, A. L.; Szweda, L. I.; Friguet, B. Mitochondrial protein oxidation and degradation in response to oxidative stress and aging. Exp. Gerontol. 41: 653-657; 2006. (Pubitemid 43866355)
240. Friguet, B.; Bulteau, A. L.; Petropoulos, I. Mitochondrial protein quality control: implications in ageing. Biotechnol. J. 3: 757-764; 2008.
241. Bakala, H.; Delaval, E.; Hamelin, M.; Bismuth, J.; Borot-Laloi, C.; Corman, B., et al. Changes in rat liver mitochondria with aging: Lon protease-like reactivity and N(epsilon)-carboxymethyllysine accumulation in the matrix. Eur. J. Biochem. 270: 2295-2302; 2003. (Pubitemid 36605579)
242. Atorino, L.; Silvestri, L.; Koppen, M.; Cassina, L.; Ballabio, A.; Marconi, R., et al. Loss of m-AAA protease in mitochondria causes complex I deficiency and increased sensitivity to oxidative stress in hereditary spastic paraplegia. J. Cell Biol. 163: 777-787; 2003. (Pubitemid 37517885)
243. Yewdell, J. W.; Anton, L. C.; Bennink, J. R. Defective ribosomal products (DRiPs): a major source of antigenic peptides for MHC class I molecules? J. Immunol. 157: 1823-1826; 1996. (Pubitemid 126449651)
244. Ding, Q.; Markesbery, W. R.; Chen, Q.; Li, F.; Keller, J. N. Ribosome dysfunction is an early event in Alzheimer's disease. J. Neurosci. 25: 9171-9175; 2005. (Pubitemid 41500825)
245. Ding, Q.; Markesbery, W. R.; Cecarini, V.; Keller, J. N. Decreased RNA, and increased RNA oxidation, in ribosomes from early Alzheimer's disease. Neurochem. Res. 31: 705-710; 2006. (Pubitemid 43886420)
246. Ding, Q.; Dimayuga, E.; Keller, J. N. Oxidative damage, protein synthesis, and protein degradation in Alzheimer's disease. Curr. Alzheimer Res. 4: 73-79; 2007.
247. Honda, K.; Smith, M. A.; Zhu, X.; Baus, D.; Merrick, W. C.; Tartakoff, A. M., et al. Ribosomal RNA in Alzheimer disease is oxidized by bound redox-active iron. J. Biol. Chem. 280: 20978-20986; 2005. (Pubitemid 40805655)
248. Shan, X.; Tashiro, H.; Lin, C. L. The identification and characterization of oxidized RNAs in Alzheimer's disease. J. Neurosci. 23: 4913-4921; 2003. (Pubitemid 36793217)
249. Ding, Q.; Cecarini, V.; Keller, J. N. Interplay between protein synthesis and degradation in the CNS: physiological and pathological implications. Trends Neurosci. 30: 31-36; 2007. (Pubitemid 44960490)
250. Kiernan, J. A.; Hudson, A. J. Changes in shapes of surviving motor neurons in amyotrophic lateral sclerosis. Brain 116(Pt 1): 203-215; 1993. (Pubitemid 23087043)
251. Rattan, S. I. Synthesis, modifications, and turnover of proteins during aging. Exp. Gerontol. 31: 33-47; 1996. (Pubitemid 26079660)
252. Ryazanov, A. G.; Nefsky, B. S. Protein turnover plays a key role in aging. Mech. Ageing Dev. 123: 207-213; 2002. (Pubitemid 33097566)
253. Vabulas, R. M. Proteasome function and protein biosynthesis. Curr. Opin. Clin. Nutr. Metab. Care 10: 24-31; 2007. (Pubitemid 44901130)
254. Dantuma, N. P.; Groothuis, T. A.; Salomons, F. A.; Neefjes, J. A dynamic ubiquitin equilibrium couples proteasomal activity to chromatin remodeling. J. Cell Biol. 173: 19-26; 2006.
255. Jarrousse, A. S.; Petit, F.; Kreutzer-Schmid, C.; Gaedigk, R.; Schmid, H. P. Possible involvement of proteasomes (prosomes) in AUUUA-mediated mRNA decay. J. Biol. Chem. 274: 5925-5930; 1999. (Pubitemid 29109251)
256. Stavreva, D. A.; Kawasaki, M.; Dundr, M.; Koberna, K.; Muller, W. G.; Tsujimura-Takahashi, T., et al. Potential roles for ubiquitin and the proteasome during ribosome biogenesis. Mol. Cell Biol. 26: 5131-5145; 2006. (Pubitemid 43955825)
257. Schubert, U.; Anton, L. C.; Gibbs, J.; Norbury, C. C.; Yewdell, J. W.; Bennink, J. R. Rapid degradation of a large fraction of newly synthesized proteins by proteasomes. Nature 404: 770-774; 2000. (Pubitemid 30212405)
258. Ezhkova, E.; Tansey, W. P. Proteasomal ATPases link ubiquitylation of histone H2B to methylation of histone H3. Mol. Cell 13: 435-442; 2004. (Pubitemid 38229815)
259. Ding, Q.; Dimayuga, E.; Markesbery, W. R.; Keller, J. N. Proteasome inhibition induces reversible impairments in protein synthesis. FASEB J. 20: 1055-1063; 2006. (Pubitemid 44943901)
260. King, M. A.; Hands, S.; Hafiz, F.; Mizushima, N.; Tolkovsky, A. M.; Wyttenbach, A. Rapamycin inhibits polyglutamine aggregation independently of autophagy by reducing protein synthesis. Mol. Pharmacol. 73: 1052-1063; 2008. (Pubitemid 351439187)
261. Busija, D. W.; Meng, W.; Bari, F.; McGough, P. S.; Errico, R. A.; Tobin, J. R., et al. Effects of ischemia on cerebrovascular responses to N-methyl-D-aspartate in piglets. Am. J. Physiol. 270:H1225-H1230; 1996.
262. Veltkamp, R.; Domoki, F.; Bari, F.; Louis, T. M.; Busija, D. W. Inhibitors of protein synthesis preserve the N-methyl-D-aspartate-induced cerebral arteriolar dilation after ischemia in piglets. Stroke 30: 148-152; 1999. (Pubitemid 29029456)
263. Massip, L.; Garand, C.; Paquet, E. R.; Cogger, V. C.; O'Reilly, J. N.; Tworek, L., et al. Vitamin C restores healthy aging in a mouse model for Werner syndrome. FASEB J. 24: 158-172; 2010.
264. Smith, K. M.; Matson, S.; Matson, W. R.; Cormier, K.; Del Signore, S. J.; Hagerty, S. W., et al. Dose ranging and efficacy study of high-dose coenzyme Q10 formulations in Huntington's disease mice. Biochim. Biophys. Acta 1762: 616-626; 2006. (Pubitemid 43903119)
265. Yang, F.; Lim, G. P.; Begum, A. N.; Ubeda, O. J.; Simmons, M. R.; Ambegaokar, S. S., et al. Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J. Biol. Chem. 280: 5892-5901; 2005. (Pubitemid 40280072)
266. Berger, Z.; Ravikumar, B.; Menzies, F. M.; Oroz, L. G.; Underwood, B. R.; Pangalos, M. N., et al. Rapamycin alleviates toxicity of different aggregate-prone proteins. Hum. Mol. Genet. 15: 433-442; 2006. (Pubitemid 43159895)
267. Lee, B. H.; Lee, M. J.; Park, S.; Oh, D. C.; Elsasser, S.; Chen, P. C., et al. Enhancement of proteasome activity by a small-molecule inhibitor of USP14. Nature 467: 179-184; 2010.
268. Rubinsztein, D. C.; Huntington, J. A. Paradoxical aggregation versus oligo-merisation properties of mutant and wild-type huntingtin fragments. Exp. Neurol. 199: 243-244; 2006. (Pubitemid 43928980)
269. Gafni, J.; Hermel, E.; Young, J. E.; Wellington, C. L.; Hayden, M. R.; Ellerby, L. M. Inhibition of calpain cleavage of huntingtin reduces toxicity: accumulation of calpain/caspase fragments in the nucleus. J. Biol. Chem. 279: 20211-20220; 2004. (Pubitemid 38623466)
270. Crocker, S. J.; Smith, P. D.; Jackson-Lewis, V.; Lamba, W. R.; Hayley, S. P.; Grimm, E., et al. Inhibition of calpains prevents neuronal and behavioral deficits in an MPTP mouse model of Parkinson's disease. J. Neurosci. 23: 4081-4091; 2003. (Pubitemid 36958427)
271. Zhang, X.; Graham, S. H.; Kochanek, P. M.; Marion, D. W.; Nathaniel, P. D.; Watkins, S. C., et al. Caspase-8 expression and proteolysis in human brain after severe head injury. FASEB J. 17: 1367-1369; 2003.
272. Clark, R. S.; Bayir, H.; Chu, C. T.; Alber, S. M.; Kochanek, P. M.; Watkins, S. C. Autophagy is increased in mice after traumatic brain injury and is detectable in human brain after trauma and critical illness. Autophagy 4: 88-90; 2008.